Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Metagenomi, Inc. is a genetic medicines company specializing in genome editing technologies. Using proprietary metagenomics, AI, and advanced molecular tools, it develops precise, durable gene editing systems for treating genetic and protein deficiency diseases. Its portfolio includes in vivo therapies for hemophilia A, secreted protein disorders, and collaborations targeting cardiometabolic conditions, aiming to deliver potentially curative, one-time treatments across multiple organs and disease areas.
This description was generated via AI from an annual report. Updated about 1 year ago.